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Purpose: Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive therapy option for inoperable liver
oligometastases. Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had
undergone ultrasound-guided breath-hold SABR.
Patients and methods: 19 patients with liver metastases of various primary tumors consecutively treated with
SABR (image-guidance with stereotactic ultrasound in combination with computer-controlled breath-hold) were
analysed regarding overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC), acute
and late toxicity.
Results: PTV (planning target volume)-size was 108 ± 109cm3 (median 67.4 cm3). BED2 (Biologically effective dose in
2 Gy fraction) was 83.3 ± 26.2 Gy (median 78 Gy). Median follow-up and median OS were 12 months. Actuarial
2-year-OS-rate was 31%. Median PFS was 4 months, actuarial 1-year-PFS-rate was 20%. Site of first progression was
predominantly distant. Regression of irradiated lesions was observed in 84% (median time to detection of
regression was 2 months). Actuarial 6-month-LC-rate was 92%, 1- and 2-years-LC-rate 57%, respectively. BED2
influenced LC. When a cut-off of BED2 = 78 Gy was used, the higher BED2 values resulted in improved local control
with a statistical trend to significance (p = 0.0999). Larger PTV-sizes, inversely correlated with applied dose, resulted
in lower local control, also with a trend to significance (p-value = 0.08) when a volume cut-off of 67 cm3 was used.
No local relapse was observed at PTV-sizes< 67 cm3 and BED2> 78 Gy. No acute clinical toxicity> °2 was observed.
Late toxicity was also≤ °2 with the exception of one gastrointestinal bleeding-episode 1 year post-SABR. A
statistically significant elevation in the acute phase was observed for alkaline-phosphatase; in the chronic phase for
alkaline-phosphatase, bilirubine, cholinesterase and C-reactive protein.
Conclusions: A trend to statistically significant correlation of local progression was observed for BED2 and PTV-size.
Dose-levels BED2> 78 Gy cannot be reached in large lesions constituting a significant fraction of this series.
Image-guided SABR (igSABR) is therefore an effective non-invasive treatment modality with low toxicity in patients
with small inoperable liver metastases.
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Standard therapy for solitary liver metastases is surgical
resection [1]. For medically or technically inoperable
patients, therapy options include radiofrequency-,
microwave- and cryo-/laser-ablation, alcohol-injection,
transarterial chemoembolisation and stereotactic ablative
radiotherapy (SABR) [2,3]. SABR is the only truly non-
invasive approach, combining high efficacy with minimal
side effects in the oligometastatic situation [4].
Dose-escalation has improved local control [5]. High-
dose liver-SABR is a technical challenge because of
respiration-induced movement and vicinity of radiosen-
sitive Organs-At-Risk (OAR [6]). The main problems are
precise tumor immobilisation as well as fast and reliable
visualisation and localisation of the lesions. Irradiation
during free-breathing with the Internal Target Volume
concept and abdominal compression would require a
relatively larger PTV compared to breath-hold defined
PTV (Planning Target Volume, due to breathing motion
[7]).
Breath-hold techniques enable tumor immobilisation
and the delivery of high doses to the PTV while max-
imally sparing the OARs [8]. Computer-controlled
breath-hold with the ABCW-system (Active Breathing
Coordinator, Elekta, Crawley, U.K.) in combination with
daily image-guidance has been shown to be feasible for
liver targets [9]. Upper abdominal tumors can be rapidly
visualised and localised with stereotactic ultrasound (B-
mode acquisition and targeting, BATW, Nomos) [10-12],
either directly or relying on surrogate structures (liver
capsule, vessels), or with on-board cone-beam-CT
(CBCT) [13] with a repeat breath-hold approach [14].
Data of large patient cohorts on local control (LC) and
survival after liver SABR are relatively rare due to lack of
large randomised studies. Given the novelty of SABR,
studies (both prospective and retrospective) with long-
term follow-up data are still rare.
In this retrospective evaluation, we intended to assess
outcome and toxicity in a unique single-institution series
of patients who received volume image-guided breath-
hold liver SABR.
Overall-survival (OS), progression-free-survival (PFS),
local control (LC), acute and late toxicity based on clin-
ical and laboratory parameters and CTC/LENT-SOMA
(Common Toxicity Criteria/ Late Effects on Normal Tis-
sues; Subjective Objective Management Analysis) scales
were evaluated.
Patients and methods
Patients
Between 2005–2010, 22 lesions in 19 consecutive
patients (15 male, 4 female; median age 69ys, range 39-
87ys) were irradiated (one re-irradiation, in 2 patients 2
lesions in 1 PTV) after informed consent. All lesionswere liver metastases of various primary tumors (10
colorectal, 1 prostate, 2 breast, 2 melanoma, 1 GIST
(Gastrointestinal Stromal Tumor), 1 oesophagus, 1 hepa-
tocellular carcinoma, 1 NSCLC (Non-Small-Cell Lung
Cancer)) which were considered to be technically or
medically inoperable by an interdisciplinary tumor-
conference. The cohort can be characterised by a rela-
tively large number of patients with poor prognosis (5
patients with extrahepatic metastases and 2 patients with
uncontrolled primaries).
Radiotherapy planning and treatment
Planning CT scans were acquired with a spiral-CT
(Somatom Emotion, thereafter Somatom Volume Zoom;
Siemens, Erlangen, Germany) with i.v. contrast, in the
portal-venous phase after an initial patient training ses-
sion in inspiratory breath-hold at approximately 70% of
vital capacity with ABCW [12]. Radiotherapy planning
was initially performed as 3-dimensional conformal
RadioTherapy (3D-CRT) with OTP, Theranostic GmbH,
Solingen, Germany and thereafter with Intensity Modu-
lated RadioTherapy (IMRT) with MonacoW, Elekta. A
pre-therapeutic MRI or PET-CT was performed and the
information was used during planning for GTV (Gross
Tumor Volume) definition. PTV was calculated from
GTV by adding a 5 mm margin radially and 10 mm in
the craniocaudal direction to compensate residual intra-
fractional error of the ABCW-based positioning [15].
Organ contours and surrogate structures needed for
ultrasound-based image guidance (portal vein, liver
veins, and liver capsule) were identified by a physician
[10,12] and were exported to BATW
Dose prescription was initially performed to the iso-
center (3D-CRT, typically in the vicinity of the median
dose) and later as the median dose in the PTV (IMRT)
with the 90% isodose line covering the PTV. Dose con-
straints for OAR were as follows: mean dose to each kid-
ney was restricted to 10 Gy, maximal dose in the spinal
cord to 25 Gy. Hot spots in >0.5 cm3 of hollow organs
(stomach/small intestine/oesophagus) were restricted to
a maximum of 8 Gy/fraction for treatments with ≤3
fractions and a maximum of 6 Gy/fraction for treat-
ments with 5 fractions. 50% of healthy liver tissue was
kept below 10 Gy [16]. Implementing results from pub-
lished literature reports regarding dose escalation and
fractionation, dose to the patients was adjusted during
the reported period and varied between single-fraction
doses of 24-30 Gy initially (depending on tumor and
liver volume) and various hypofractionated regimens
with the current, final protocol prescribing 5x12Gy every
other day.
Biologically effective dose in 2 Gy fractions (BED2)
was calculated using the linear-quadratic model with an
assumed α/β ratio of 10 as described [6]:
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(SynergyW, Elekta). Daily image-guidance was performed
with BATW and beginning in 2005 with additional CBCT
with image acquisition in repeated breath-hold (XVIW,
X-Ray Volume Imaging, Elekta; [17]). CT-structures,
contours of PTV and OAR/surrogate structures were
imported into the BATW- and XVIW-system as 3D struc-
tures in DICOM (Digital Imaging and Communication
in Medicine) format. Although the lesion to be treated
could not always directly be visualized by ultrasound,
the liver as a whole as well as surrogate structures (por-
tal vein, liver veins) could be precisely visualized and
matched and served as surrogates for positioning of the
target [10,12] (Figure 1A-D). No implanted fiducials
were used for EPID localisation to establish a completely
non-invasive treatment modality [10].
Linac, BATW and ABCW were not connected by inter-
faces. Breath-hold and imaging or beam were synchro-
nized manually. When CBCT was used (used for initial
positioning/assessment of overall geometric situation
and rarely exclusively if BATW was not available,
Figure 1E-F), planning-CT images were matched online
with the daily CBCT images acquired in repeat breath-
BED2¼ Dx dþ α=βð Þ= 2þ α=βð Þ:Figure 1 Daily positioning with BATW. Before (A-B) and after (C-D)
position correction. Surrogate structures and PTV are marked with
colors: orange, liver; green, PTV; blue, portal vein; red, liver veins. E-F:
Alternative repeat breath-hold positioning with CBCT. Green, CBCT;
magenta, planning-CT.hold [17] using manual fusion and with respect to soft-
tissue anatomy. On-line surveillance of breath-hold was
performed based on the continuous acquisition of MV-
frames (EPID; Electronic Portal Imaging Device) during
irradiation allowing position verification of the dia-
phragm. Intrafractional error was controlled/corrected
with BATW at least two times per fraction.
Patient follow-up (FU) was scheduled 6 weeks after
radiotherapy and every 3 months thereafter with clinical
examination, liver-MRI with i.v. contrast (or CT/PET-
CT, if MRI contraindicated) and laboratory values. An
assessment of tumor response was performed using the
RECIST (Response Evaluation and Criteria in Solid
Tumors) criteria. Response was graded as complete re-
sponse (CR), partial response (PR), stable disease (SD) or
progression.
Acute toxicity was defined as symptoms observed in
the first 90 days after radiotherapy, with later symptoms
being scored as late toxicity.
Data analysis
OS (Overall-Survival), PFS (Progression-Free-Survival)
and LC (Local Control) were recorded and subject to ac-
tuarial analysis. Acute (first 90 days) and late toxicity
(>90 days) was evaluated based on clinical symptoms
and laboratory values (graded based on the CTC-scale in
the acute phase and on the LENT-SOMA criteria in the
late phase.
Recorded clinical endpoints/symptoms were general
condition, abdominal pain, appetite, nausea, vomiting,
fever and skin symptoms for assessing acute toxicity; ab-
dominal pain, hepatomegaly, edema, weight gain due to
edema/ascites, vigilance, bleedings, ascites and rib frac-
ture for late toxicity.
The following laboratory values were analysed: ALAT
(alanine-aminotransferase), ASAT (aspartate-aminotrans-
ferase), GGT (gamma-glutamyl-transferase), LDH (lac-
tate-dehydrogenase), AP (alkaline-phosphatase), BR
(bilirubine), aPTT (activated partial thromboplastine-time
), thrombocyte-count, serum albumin, CHE (cholinester-
ase), prothrombin activity, blood urea, CRP (C-reactive-
protein).
PTV-coverage was analysed based on relevant para-
meters (D99 (dose encompassing 99% of the PTV), min-
imal, maximal, mean and median PTV-dose. Volume of
healthy liver tissue was documented. Depth of breath-
hold and breath-hold duration was also evaluated.
Statistics
Statistical analysis was performed with the SAS-software
, release 9.01 (SAS, Cary, NC, USA). OS was calculated
from the day of irradiation until either the day of death
(event) or the day of the last FU (follow-up, censored
data). PFS was calculated from the day of irradiation
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last FU without relapse (censored data when at the last
FU the patient lived without any evidence of progres-
sion). LC was calculated from the day of irradiation until
either the day of local progression or death (event) or
the last FU without local progression (censored data
when at the last FU the patient lived without any evi-
dence of local progression). Kaplan-Meier-curves for OS,
PFS and LC were calculated in order to assess median
survival/control times. Correlation of local progression
as a binary parameter and PTV size and BED2 was ana-
lysed with the logistic regression test. Correlation of the
local control time with PTV size and BED2 was analysed
by the Kaplan-Meier log-rank test. Differences between
pre- and post-therapeutic laboratory values were tested
using the Dunnett-test. Test results were considered sig-
nificant when p-values were <0.05.Results
Radiotherapy data
All patients managed to achieve sufficient repeat breath-
hold with ABCW for an IMRT (3 patients) or 3DCRT
(16 patients) radiotherapy session. Breath-hold time was
17.2 ± 3.6 seconds. Depth of breath-hold was 1.5 ± 0.4
litres (threshold value in ABCW). Volume of healthy liver
tissue was 1401 ± 350 cm3.
BED2 was 83.3 ± 26.2 Gy (median 78 Gy, range 44-
150 Gy). 7 patients were treated with a BED2 of <78 Gy,
12 patients with a BED2 of ≥78 Gy. PTV dose-data for
different fractionation schedules are summarised in
Table 1. PTV-size was 108 ± 109cm3 (median 67.4 cm3,
range 11–419 cm3).Follow-up (FU), Overall-Survival (OS), Progression-free-
survival (PFS) and Local Control (LC)
Median FU was 12 months (14 ± 12 months; MV±SD,
mean value ± standard deviation). Median FU was
12 months (18 ± 15 months) for living patients. 5
patients are alive, 13 patients have died and one patient
has been lost to FU (released from jail, not traceable).Table 1 Mean, median, minimal and maximal absolute doses
PTV dose
parameter (Me
single-fraction 2 frac
SABR (n = 12) (n = 2
Dmean 26,07 ± 1,81 27,16
Dmedian 26,11 ± 1,79 27,12
Dmin 23,9 ± 1,85 21,23
Dmax 27,26 ± 2,06 29,3 ±
D99 24,2 ± 2,62 25,65
D99: Dose encompassing 99% of the PTV.
Abbreviations: Dmin, minimal dose; Dmax, maximal dose; Dmedian, median dose; DmeaActuarial median OS was 12 months (15 ± 13 months;
Figure 2A). Actuarial 2-year-OS was 31%. Cause of death
was systemic metastases outside the liver in 5 patients,
progression of the primary tumor (oesophagus/colorec-
tal) in 5 patients, an episode of acute gastrointestinal
bleeding in one patient and hepatic insufficiency in one
patient, mainly induced by hemochromatosis and liver
cirrhosis that had been prevalent over several years. In
one patient, the cause of death could not be determined
unequivocally but brain metastases were suspected clin-
ically when therapeutic measures were halted because of
deteriorating general condition.
Median PFS was 4 months (8 ± 8 months; Figure 2B),
actuarial 1-year PFS was 20%. Progression pattern was
mainly distant (a total 17 patients experienced systemic
progression; 10 patients had a second liver metastasis, 9
patients had extrahepatic distant metastases in brain/
lung/bones/kidney/adrenal-gland/spleen/peritoneum/ab-
dominal-wall/abdominal-lymph nodes).
Median LC has not yet been reached. Actuarial 6-
month LC-rate was 92%, 2-year LC rate was 57%
(Figure 2C). Most patients died due to systemic metasta-
ses or progress of the primary (77%) with locally con-
trolled irradiated lesions.
Correlation of Local Progression as a binary parameter
and PTV size and BED2 was analysed with the logistic
regression test. PTV size has shown a trend towards
lower local control in larger lesions (p = 0.0894). How-
ever, correlation of local control time to PTV size (cut-
off 67ccm) with the Kaplan Meier Log-rank test has not
shown statistical significance (p = 0.2412; Figure 3A).
Local recurrences were only observed for patients re-
ceiving a BED2≤ 78 Gy (5 patients). BED2 did not show
a significant correlation in the logistic regression
(p = 0.1926) but a trend to significance at a dose cut-off
of 78 Gy with the Kaplan-Meier log-rank test
(p = 0.0999; Figure 3B).
In 16 patients, size-reduction of the irradiated lesion
was observed, in 3 patients, lesions remained unchanged.
Median time to response was 2 months (3 ± 1 months,
typically at first reported FU). Complete response of theto the PTV for different fractionation regimens
Dose (Gy)
an value± Standard deviation)
tions 3 fractions 5 fractions
) (n = 3) (n = 5)
± 3,87 33,92 ± 1,37 59,51 ± 0,58
± 3,88 34,34 ± 1,47 59,89 ± 0,66
± 3,31 26,56 ± 2,46 50,92 ± 8,00
5,44 36,3 ± 0,89 62,48 ± 1,24
± 4,0 32,6 ± 2,55 57,54 ± 3,19
n, mean dose, PTV, Planning Target Volume.
Figure 2 Kaplan-Meier-curves for all patients. A.) Overall-survival. B.) Progression-free-survival. C.) Local control.
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Figure 3 A) Local control of patients with BED2≥ 78 Gy (red) and <78 Gy (black), p = 0.0999 (trend to significance; Kaplan-Meier log-
rank test). B) Local control of patients with PTV< 67 cm3 (red) and ≥67 cm3 (black), p = 0.2412, not significant.
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progression after initial regression was observed in 5
patients after a median of 10 months.
A representative patient example is shown in Figure 4.
Acute toxicity
No acute toxicity>CTC grade 2 was observed. The fol-
lowing symptoms were detected: slight upper-abdominal
pain (3patients), appetite loss (4patients), nausea
(3patients), slight vomiting (2patients) and fatigue
(4patients). Fever was observed in only 1 patient, how-
ever, this was considered a dexamethasone side-effect.
One patient developed a clinically indolent but radio-
logically evident and lab-proven cholangitis, which was
successfully treated with interventional endoscopy. No
clinical signs of pneumonitis and no acute gastrointes-
tinal bleedings were observed.
A significant elevation compared to pre-therapeutic
values in the acute phase was observed only for AP
(p = .0274), indicating an intrahepatic cholestasis, which,
however, in most patients was clinically unapparent (in
one patient radiologically detectable). ALAT, ASAT,
GGT, LDH, BR, aPTT, thrombocyte count, albumin,
CHE, prothrombin activity, blood urea and CRP did not
show significant changes.
Chronic toxicity
Late toxicity was difficult to analyse in this cohort of
patients with advanced tumor stages due to progressive
disease causing symptoms similar to radiation-associated
processes/radiation sequelae. Several patients who devel-
oped multiple liver metastases, suffered from ascites,
edema, weight gain and other signs of hepatic insuffi-
ciency. Patients without hepatic progression did not de-
velop any chronic toxicity regarding the upper abdomen.
No rib fractures were observed.One patient experienced an episode of endoscopically
confirmed gastrointestinal bleeding 1 year post-igSABR.
An anatomical correlation of the endoscopic report
about the bleeding with the radiation plan was per-
formed. No spatial correlation could be found, however,
a “matching” of an endoscopy report with planning CT
is certainly not possible.
A significant elevation compared to pre-therapeutic
values in the chronic phase was observed for AP
(p = 0.0016), BR (p = 0.0222), CHE (p = 0.0056) and CRP
(p = 0.0320). A trend to significance was observed for
GGT (p = 0.0673). ALAT, ASAT, LDH, aPTT, thrombo-
cytes, albumine, prothrombin activity and blood urea did
not show significant changes.
Discussion
In SABR of liver metastases, dose escalation has been
shown to be essential to increase local control [1]. Tech-
nical improvement of planning and delivery have
enabled dose escalation, within the confines of liver tol-
erance dose-volume constraints [18]. A relatively high
interfractional accuracy was achievable with frame-based
positioning in free-breathing with abdominal compres-
sion. Daily soft-tissue image-guided frameless stereotaxy
with either ultrasound or cone-beam CT have mainly
replaced the frame-based setup [19]. Daily sonographic
imaging of the target lesion or intrahepatic surrogate
structures allows fast imaging in breath-hold and in the
future even tracking [10,12,14]. There are no large pro-
spective studies evaluating the clinical results of SABR
of the liver. The present cohort is the first clinically
reported series of igSABR using an ultrasound-guided
computer-controlled breath-hold setup.
Radiation-induced change in the liver include
Radiation-Induced Liver Disease (RILD) with a syn-
drome of anicteric ascites and hepatomegaly, elevation
Figure 4 Radiation plan, pretreatment- and posttreatment MRI of a patient with two small liver metastases of a melanoma treated
with 1x26Gy in 1 PTV. The lesions remain locally controlled (follow-up of 4 years).
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Despite the detected histological and radiological radi-
ation reactions, clinical symptoms after liver SABR have
been reported in several studies to be low with max-
imum side effect reaching grade 3 [3]. Similar to litera-
ture data, clinical acute and late toxicity did not exceed
CTC/ LENT-SOMA grade 2 in our collective. Solely one
episode of gastric bleeding 1-year post-SBRT was
detected. Based on localisation of the treated lesion and
the source of bleeding, association with igSABR is un-
likely but cannot be excluded with certainty in
retrospect.
Outcome cannot be compared according to primary
malignancy in the published series because of small
numbers of patients treated for individual disease. Vary-
ing fractionation schedules in different series and also
within one series, however, can be compared calculating
BED2. In addition, most studies evaluate mixed cohorts
of lung and liver SABR without a clear differentiation of
these two populations.
Lesions receiving BED2< 78 Gy did not achieve satis-
factory local control in this series. We analysed the avail-
able studies in the literature also with calculating BED2
and compared these to our data (Table 2, [5,21-26]).
Comparing all published studies, a maximum 1-yr localTable 2 Comparison of available studies in the literature
Study Irradiated liver
metastases (n)
Nominal total
dose/single dose (G
Katz et al., 2007 [21] 69 30-55/2-6
McCammon et al., 2009 [5] 81 3 dose levels:
1.)< 36/12
2.) 36-54/12-18
3.) 54/18
Milano et al., 2008 [22] 121 10-20/10-20
Goodmann et al., 2010 [23] 40 18-30/18-30
Iwata et al., 2010 [24] 12 50-55/5-5.5
Rusthoven et al., 2009 [25] 63 36-60/12-20
Lee et al., 2009 [26] 68 42-60/7-10
Current series JBH et al. 22 24-60/24-12
BED2 and PTV volumes were calculated by JBH et al. (V = 4/3πr3; median/range) in tcontrol rates of 57% was reported, if BED2< 50 Gy was
applied in large PTVs (range up to >400ccm).
Our cohort with mixed primary tumor entities repre-
sented an unfavourable patient subset (several patients
had extensive metastatic disease). Fractionation schedule
and nominal doses varied over the evaluated period,
reflecting escalation of published doses. Doses used ini-
tially can be regarded as too low in retrospect with the
current knowledge. The daily repositioning technique
used for this series was unique (computer-controlled
breath hold in combination with sonographic imaging)
compared to similar analyses in the literature. Median
survival of 12 months and a 1-year LC rate of 57% are,
however, comparable to literature data. Due to the rela-
tively small and heterogeneous collective, we could not
establish a formal dose-effect relationship. No local re-
lapse was observed at PTV-sizes smaller as 67 cm3 and
doses >78 Gy BED2 and a trend to statistically signifi-
cant correlation was observed for both parameters. This
dose level could not be reached due to threshold doses
in large lesions constituting a significant fraction of this
series. That the results are not highly statistically signifi-
cant, is probably due to the small patient number and
relatively large range of applied BED2 (between 44-
150 Gy) and PTV-sizes (between 21-419 cm3).y)
BED2 (Gy) Lesion size
(ccm)
Median FU
(months)
1-year LC
rate (%)
40-73* 0.1-950* 14.5 76
3 levels*: 2.8-370 8.2
1.) 39 1.) 40
2.) 39-58 2.) 88
3.) 58 3.) 100
16-50 0.2-422 Not stated 57
42-100* 0.8-146 17 77
62-71* 0.9-22* 14.5 86
66-150* <113* 16 95
59-100* 1.19-3000 10.8 71
44-150 11-419 12 57
he cases marked with *.
Boda-Heggemann et al. Radiation Oncology 2012, 7:92 Page 8 of 9
http://www.ro-journal.com/content/7/1/92Steep dose gradients and precise intrafractional reposi-
tioning before each fraction is possible with the cur-
rently available commercial methods. Non-invasive
markerless intrafractional monitoring of tumor position
is, however, not yet possible with commercially available
systems with ultrasound-based online monitoring being
developed [27]. Precise positioning and online surveil-
lance will probably allow further reduction of safety mar-
gins (for an average CTV size of 113ccm the reduction
of safety margin of 5 mm would spare 66ccm healthy
liver tissue). This would enable irradiation of larger
lesions with higher doses.
Results may further be improved by parallel adminis-
tration of chemotherapeutic agents for radiosensitiza-
tion. Large studies are needed to optimize clinical
outcome and characterise radiological and clinical side
effects.
These data show that, if the application technique, le-
sion size and dose to OAR allow the application of doses
approaching the ablation threshold dose calculated by
Fowler and Tome [28], then SABR of the liver with
photons is an effective, non-invasive and safe treatment
method. Similar results have been observed for SABR of
the lung [29,30]. For large lesions (>70 cm3), if no
BED2> 80 Gy can be reached without a high risk of side
effects, results are still not satisfactory. Limiting factor
for dose escalation in liver SABR is the radiation toler-
ance of healthy liver tissue. After introduction of mod-
ern highly precise techniques with steep dose gradients
(VMAT (Volumetric Modulated Arc Therapy) [31,32],
IMRT) with daily 3D image guidance, maximal efficacy
of photon-based SBRT has been reached.
New radiotherapy techniques may provide further
optimization of dose distributions [33]. Detection of
intrafraction motion by online tracking may facilitate ap-
plying sufficiently high doses to larger lesions.
Conclusions
Breath-hold image guided SABR of liver metastases is an
effective and safe treatment modality for inoperable liver
metastases.
No local relapse was observed at PTV-sizes< 67 cm3
and BED2> 78 Gy and a trend to statistically significant
correlation with local control was observed for both
parameters. However, this dose level cannot be reached
in large lesions constituting a significant fraction of this
series.
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